Idorsia Ltd - Asset Resilience Ratio

Latest as of September 2025: 1.63%

Idorsia Ltd (IDIA) has an Asset Resilience Ratio of 1.63% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read IDIA total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CHF7.39 Million
≈ $9.35 Million USD Cash + Short-term Investments

Total Assets

CHF454.57 Million
≈ $574.70 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Idorsia Ltd's Asset Resilience Ratio has changed over time. See Idorsia Ltd shareholders equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Idorsia Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Idorsia Ltd.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CHF0.00 0%
Short-term Investments CHF7.39 Million 1.63%
Total Liquid Assets CHF7.39 Million 1.63%

Asset Resilience Insights

  • Limited Liquidity: Idorsia Ltd maintains only 1.63% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Idorsia Ltd Industry Peers by Asset Resilience Ratio

Compare Idorsia Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 3.28%
Summit Therapeutics PLC
NASDAQ:SMMT
Biotechnology 0.00%
Argen-X
F:1AE
Biotechnology 25.67%
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
Biotechnology 0.21%
R&G PharmaStudies Co. Ltd. A
SHE:301333
Biotechnology 35.96%
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
Biotechnology 79.48%
Innovita Biological Technology Co. Ltd. A
SHG:688253
Biotechnology 70.49%
Sunmax Biotechnology Co Ltd
TWO:4728
Biotechnology 10.53%

Annual Asset Resilience Ratio for Idorsia Ltd (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Idorsia Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 3.55% CHF17.98 Million
≈ $22.73 Million
CHF505.89 Million
≈ $639.59 Million
+1.00pp
2023-12-31 2.55% CHF12.76 Million
≈ $16.14 Million
CHF500.00 Million
≈ $632.13 Million
-33.98pp
2022-12-31 36.53% CHF330.33 Million
≈ $417.62 Million
CHF904.18 Million
≈ $1.14 Billion
-26.64pp
2021-12-31 63.17% CHF936.77 Million
≈ $1.18 Billion
CHF1.48 Billion
≈ $1.87 Billion
-0.87pp
2020-12-31 64.04% CHF919.22 Million
≈ $1.16 Billion
CHF1.44 Billion
≈ $1.81 Billion
-9.96pp
2019-12-31 74.00% CHF743.07 Million
≈ $939.44 Million
CHF1.00 Billion
≈ $1.27 Billion
+8.34pp
2018-12-31 65.66% CHF923.67 Million
≈ $1.17 Billion
CHF1.41 Billion
≈ $1.78 Billion
+0.58pp
2017-12-31 65.08% CHF840.75 Million
≈ $1.06 Billion
CHF1.29 Billion
≈ $1.63 Billion
-14.47pp
2016-12-31 79.55% CHF727.98 Million
≈ $920.36 Million
CHF915.12 Million
≈ $1.16 Billion
--
pp = percentage points

About Idorsia Ltd

SW:IDIA Switzerland Biotechnology
Market Cap
$1.14 Billion
CHF905.23 Million CHF
Market Cap Rank
#10420 Global
#126 in Switzerland
Share Price
CHF3.68
Change (1 day)
+1.60%
52-Week Range
CHF1.28 - CHF4.70
All Time High
CHF33.62
About

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the… Read more